DocGo Announces First Quarter 2026 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- Outlook Therapeutics (OTLK) halted, news pending
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
DocGo (DCGO) Misses Q1 EPS by 3c, Beats on Revenue; Offers FY26 Revenue Guidance
May 11, 2026 4:09 PM EDTDocGo (NASDAQ: DCGO) reported Q1 EPS of ($0.15), $0.03 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $75.6 million versus the consensus estimate of $72.43 million.
GUIDANCE:
DocGo sees FY2026 revenue of $300-315 million, versus the consensus of $298.7... More
